PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced the filing of three additional U.S. Provisional Patent Applications covering its latest discoveries. This bring the total number of provisional applications filed by PsyBio to nineteen.
The National Park Service posted a request recently warning visitors not to lick the Sonoran Desert Toad (Incilius alvarius), as reported online by the Smithsonian Magazine.1 The report describes that widespread use of 5-MeO-DMT could have disastrous effects for Sonoran Desert Toads and, as a result, that conservationists are urging people to use synthetic alternatives.1
“The call for a synthetic alternative for 5-MeO-DMT highlights the intrinsic potential value of PsyBio’s platform technology as it facilitates the biosynthetic production of these types of molecules. Biosynthesis is a more environmentally sound, faster, and cost-effective way to manufacture these types of molecules than chemical synthesis without endangering any species of toad or other natural creature. These additional patent filings demonstrate PsyBio’s commitment to developing and protecting intellectual property with respect to biosynthetic tryptamine and phenylethylamine production for the development of psycho-targeted molecules as novel therapeutic candidates while protecting our environment and the many species living across the globe.”
Michael Spigarelli, MD, PhD, MBA, PsyBio’s Chief Medical and Chief Scientific Officer
The three provisional patent applications comprise advancements concerning production methodology, host strains and processes of production that further support and allow PsyBio’s novel production platform methodology to be patent protected including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT, which is environmentally safer than synthetic production methodology. These filings demonstrate the company’s commitment to value creation, while both promoting scientific and methodologic advancements in the field and demonstrating its Environmental, Social, and Governance (ESG) commitment.
“PsyBio has long been interested protecting the environment by developing biosynthetic methodology that we believe is less toxic and safer to all species that share our planet. It continues ongoing strategic efforts to comprehensively cover the biosynthetic landscape for the development of psycho-targeted therapeutic candidates with the goal to improve mental and neurological health,” stated Evan Levine, PsyBio’s Chief Executive Officer. “With these provisional application filings, PsyBio furthers its leadership role within this field insuring intellectual property protection, critical for PsyBio and ultimately important for our investors as well as the environment.”
About PsyBio Therapeutics Corp
PsyBio Therapeutics is an intellectual property driven biotechnology company developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.